1
TITLE: Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial (J Neurol, (2014), 261, (2101-2111), 10.1007/s00415-014-7446-0)
AUTHORS: Ziemssen, T; Bajenaru, OA; Carrá, A; de Klippel, N; Correia de Sá, J; Edland, A; Frederiksen, JL; Heinzlef, O; Karageorgiou, KE; Lander Delgado, RH; Landtblom, AM; Macías Islas, MA; Tubridy, N; Gilgun Sherki, Y;
PUBLISHED: 2015, SOURCE: Journal of Neurology, VOLUME: 262, ISSUE: 1
INDEXED IN: Scopus
2
TITLE: COPTIMIZE: a two-year observational survey of patients with relapsing remitting multiple sclerosis switching to glatiramer acetate 20 mg daily  Full Text
AUTHORS: Ziemssen, T; Bajenaru, O; Carra, A; de Klippel, N; de Sa, J; Edland, A; Frederiksen, J; Heinzlef, O; Karageorgiou, K; Landtblom, AM; Macias Islas, MM; Tubridy, N; Gilgun Sherki, Y;
PUBLISHED: 2013, SOURCE: 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS in MULTIPLE SCLEROSIS JOURNAL, VOLUME: 19, ISSUE: 11
INDEXED IN: WOS